| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $10,517,842 ) (Continued on the next page) |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA054268 | MOUD Comparative Effectiveness Study | 000 | 5 | NIH | 4/7/2025 | $542,395 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01CA299475 | Development of Systems and Education for Cervical Cancer prevention (DOSE-CC) | 000 | 1 | NIH | 4/17/2025 | $753,446 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL165097 | From Hypertensive Pregnancy to Heart Health: Understanding and Addressing Multi-Level Barriers to Cardiovascular Health after Hypertensive Disorders of Pregnancy | 000 | 2 | NIH | 1/18/2025 | $92,614 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL165097 | From Hypertensive Pregnancy to Heart Health: Understanding and Addressing Multi-Level Barriers to Cardiovascular Health after Hypertensive Disorders of Pregnancy | 000 | 2 | NIH | 1/18/2025 | $88,838 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01MH109651 | Elucidating mechanistic connections between guidance signaling, microtubule regulation, and growth cone steering | 000 | 9 | NIH | 11/22/2024 | $370,064 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DA061939 | Community-Engaged Development of a Peer Breastfeeding Support Intervention for Mothers with Opioid Use Disorder | 000 | 1 | NIH | 1/23/2025 | $193,550 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL168098 | Identification of a mechanosensor in juxtaglomerular cells for the regulation of renin synthesis and secretion | 000 | 2 | NIH | 12/24/2024 | $640,376 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD109005 | Investigating structural maternal health inequities among Black reproductive aged women in Georgia; a mixed methods and multi-level approach | 001 | 4 | NIH | 4/24/2025 | $468,191 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD109005 | Investigating structural maternal health inequities among Black reproductive aged women in Georgia; a mixed methods and multi-level approach | 005 | 4 | NIH | 6/11/2025 | $2,644 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD109005 | Investigating structural maternal health inequities among Black reproductive aged women in Georgia; a mixed methods and multi-level approach | 005 | 4 | NIH | 6/11/2025 | $461,570 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | P30HS029752 | Boston Health Equity & community-Aligned Learning Health System (Boston-HEALHS) | 000 | 2 | AHRQ | 11/18/2024 | $978,045 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 00 | 3 | HRSA | 5/27/2025 | $399,026 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH127308 | Adaptation and assessment of a common element treatment protocol designed to improve mental health in forcibly displaced populations | 000 | 4 | NIH | 2/13/2025 | $184,034 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DA033211 | Advancing Clinical Research Training within Addiction Residency Programs | 002 | 12 | NIH | 5/2/2025 | $366,591 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH128639 | Medicaid Accountable Care Organizations (ACO) and Quality of Care for Adults with Serious Mental Illness (SMI) | 000 | 4 | NIH | 3/13/2025 | $189,432 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD019068 | Adapting an Evidence-Based Intervention to Improve the Hospital Discharge Process for Patients with Limited English Proficiency | 002 | 3 | NIH | 4/20/2025 | $162,187 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32MH135857 | Boston University Medical Campus- Massachusetts General Hospital Global Psychiatric Clinical Research Training Program | 000 | 2 | NIH | 6/9/2025 | $420,367 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R21CA286402 | Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors | 001 | 2 | NIH | 6/11/2025 | $24,675 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R21CA286402 | Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors | 000 | 2 | NIH | 1/8/2025 | $222,077 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK138309 | Effectiveness Trial to Support Adoption of Hybrid Closed Loop Therapy in Underserved Adults with Type 1 Diabetes: Impact of System Functionality and Features on Lived Experience | 000 | 2 | NIH | 12/19/2024 | $854,975 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI167740 | Characterization of HIV-1 IgA bNAbs and ADCP function | 002 | 5 | NIH | 5/1/2025 | $807,667 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an inherent bias in neuroprognostication: A collaboration between the US and Brazil to reduce the impact of Self-fulfilling Prophecy in cardiac ARrEst (SPARE) | 000 | 2 | NIH | 11/26/2024 | $532,674 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI167740 | Characterization of HIV-1 IgA bNAbs and ADCP function | 005 | 5 | NIH | 6/4/2025 | $266,604 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03HL171172 | Developing an assessment toolkit and training for teleconsultation as an intervention to improve prehospital patient safety in children | 000 | 2 | NIH | 4/16/2025 | $147,946 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R56AI186777 | Mycobacterium tuberculosis disease effect on HIV-1 immunity, evolution, and persistence | 000 | 1 | NIH | 6/11/2025 | $711,993 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 000 | 2 | NIH | 4/22/2025 | $716,458 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D4054828 | Graduate Psychology Education Programs | 00 | 1 | HRSA | 6/11/2025 | $449,998 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08DA058052 | Impact of initial buprenorphine prescribing strategies on retention in care for patients with opioid use disorder | 000 | 3 | NIH | 4/7/2025 | $186,527 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA058367 | PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | 000 | 3 | NIH | 6/18/2025 | $1,113,072 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 000 | 4 | NIH | 3/21/2025 | $372,536 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | S10OD038188 | Utilization of BioDot Omnia Automated Liquid Dispensing/Handling System to Enhance the Efficiency and Accuracy of High Throughput Biological Assays | 000 | 1 | NIH | 5/7/2025 | $248,756 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | S10OD038188 | Utilization of BioDot Omnia Automated Liquid Dispensing/Handling System to Enhance the Efficiency and Accuracy of High Throughput Biological Assays | 000 | 1 | NIH | 5/7/2025 | $1 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK118267 | Nucleophosmin Centered Diagnostics and Treatment of Ischemic Acute Kidney Injury | 001 | 6 | NIH | 4/8/2025 | $471,531 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23NS116033 | Dynamic Risk Prediction of Life-Threatening Mass Effect After Ischemic Stroke | 001 | 5 | NIH | 5/5/2025 | $2,660 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23NS116033 | Dynamic Risk Prediction of Life-Threatening Mass Effect After Ischemic Stroke | 000 | 5 | NIH | 3/24/2025 | $216,099 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133404 | Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | 000 | 4 | NIH | 4/23/2025 | $577,631 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL178832 | Niche-specific endothelial mechanisms regulating the extravasation of hematopoietic stem cells | 000 | 1 | NIH | 4/29/2025 | $734,607 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA055488 | Persistent HIV-1 expression and microglia dysfunction | 000 | 5 | NIH | 5/7/2025 | $729,537 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HS028814 | Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections | 001 | 4 | AHRQ | 6/5/2025 | $483,567 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DA061933 | Promoting positive parenting for mothers with OUD: Implementation of a video-coaching intervention in pediatrics | 000 | 1 | NIH | 4/2/2025 | $193,752 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DA054363 | Retention and Re-Engagement in Treatment for Addiction following Serious Injection Related Infections (RETAIN) | 000 | 5 | NIH | 5/15/2025 | $189,432 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01HL151902 | Assessing the burden of dementia in transgender populations | 001 | 4 | NIH | 3/25/2025 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01HL151902 | Assessing the burden of dementia in transgender populations | 000 | 4 | NIH | 3/25/2025 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R34MH137223 | Developing measures to improve access to integrated mental health care services in under-resourced global settings | 000 | 1 | NIH | 11/4/2024 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL155451 | Targeting PGC-1a for the treatment of sickle cell disease | 000 | 3 | NIH | 5/22/2025 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | NU58DP007538 | CHAMPS National | 01 | 2 | CDC | 12/18/2024 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9746074 | Special Projects of National Significance - Demonstration/Implementation Sites | 03 | 3 | HRSA | 6/9/2025 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9746074 | Special Projects of National Significance - Demonstration/Implementation Sites | 02 | 3 | HRSA | 12/23/2024 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R13DA052198 | Substance Use Modeling Consortium Workshop to Support the Public Health Response to the Overdose Crisis in North America | 002 | 4 | NIH | 4/2/2025 | $37,812 |
|
